PLGA‐particle‐based vaccine induces SARS‐CoV‐2‐specific antibody and T‐cell responses

Ähnliche Einträge

• The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19
  von: Henrietta Papp, et al.
  Veröffentlicht: (2024)
• Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study
  von: Sofia Attelind, et al.
  Veröffentlicht: (2026)
• Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS‐CoV‐2: AGILE CST‐3a/b
  von: B. Thompson, et al.
  Veröffentlicht: (2025)
• Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells
  von: Gautham Gampa, et al.
  Veröffentlicht: (2024)
• Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐CoV‐2 infection
  von: E. Challenger, et al.
  Veröffentlicht: (2025)